Biostock posted last week's epic post (which I plus one'd) regarding his interpretation/analysis of why FDA did what it did and approve a sub-par drug without much evidence of efficacy really consolidated what seems to be happening and after reading his post and thinking about his reasoning - I wholeheartedly agree with him.
We have been dealing with the beta-amyloid plaque clearance process for 30+ years now. It has been the MO of dementia researchers and clinicians that there is a correlation between plaque aggregation and level of cognitive decline and, to paraphrase many a lecturer that I have heard, that this evidence points towards the theory that if we just "clear the plaques" we may halt cognitive decline - I learned in medical school and further into residency (my NYU Neurology residency was from 2008 - 2011) that this was the way to get to the holy grail of dementia treatment.
Yet - evidence all points to this theory as being a fallacy.
Correlation does not equate to causation.
I used to post a lot more and in a lot more detail some 4+ years ago on this message board and the old YMB regarding my impressions that many neurological disorders that are seemingly different in presentation - may all be related to one common pathophysiological process - involving neuroinflammation.
Depending on the age of the patient, the genotype and environmental factors - this pathophysiological process may progress to present as a clinical phenotype - Alzheimers for one patient, parkinsons for another patient, autistic spectrum disorder for a young patient, etc.
If there was a therapeutic that could seemingly halt the chronic neuroinflammatory process at its herald steps and allow the cells back to "homeostasis" - then many seemingly different neurodegenerative disorders may be treated with this one, broad spectrum drug.
So - I placed a HUGE risk on Anavex in 2015 when I finally found a potential therapeutic that could work on chronic neuroinflammation and have remained steadfast in my belief that Anavex has "figured it out."
While Anavex has been doing yeomans work swimming upstream in a climate where most researchers were swimming downstream in the river of beta-amyloid plaque clearance, our little company was getting no respect. We were the contrarians and you all know how contrarians are treated by their conventional contemporaries - as "misfits" or worse.
So the FDA HAD TO FINALLY APPROVE a chit drug to allow it to fail dramatically in the public eye - to force the clinicians to go another way.
I think biostock is intelligent and astute enough to see the writing on the wall - let beta-amyloid plaque clearance theory FAIL quickly to allow room for the contrarian misfits like Anavex to take up the reins and take the helm of neurodegenerative disease treatment!
As Biostockclub would say - "we got this!"
Good luck to all longs!
Market Data 
Markets 
AI
